Found: 16
Select item for more details and to access through your institution.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 396, doi. 10.1002/ajh.27206
- By:
- Publication type:
- Article
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 8, p. 803, doi. 10.1002/ajh.23745
- By:
- Publication type:
- Article
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 2, p. 145, doi. 10.1002/ajh.23600
- By:
- Publication type:
- Article
Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 12, p. 967, doi. 10.1002/ajh.22163
- By:
- Publication type:
- Article
Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 8, p. 524, doi. 10.1002/ajh.21448
- By:
- Publication type:
- Article
ESAs: Not a convicted felon but still a suspect.
- Published in:
- American Journal of Hematology, 2008, v. 83, n. 11, p. 880, doi. 10.1002/ajh.21282
- By:
- Publication type:
- Article
Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma.
- Published in:
- American Journal of Hematology, 2008, v. 83, n. 9, p. 697, doi. 10.1002/ajh.21239
- By:
- Publication type:
- Article
Intravenous iron: A useful therapeutic tool but not a panacea.
- Published in:
- American Journal of Hematology, 2008, v. 83, n. 7, p. 521, doi. 10.1002/ajh.21189
- By:
- Publication type:
- Article
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor- κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
- Published in:
- British Journal of Haematology, 2006, v. 135, n. 5, p. 688, doi. 10.1111/j.1365-2141.2006.06356.x
- By:
- Publication type:
- Article
Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.
- Published in:
- British Journal of Haematology, 2006, v. 134, n. 6, p. 620, doi. 10.1111/j.1365-2141.2006.06230.x
- By:
- Publication type:
- Article
Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes.
- Published in:
- 2003
- By:
- Publication type:
- Letter
HLA variations in patients with diffuse large B-cell lymphoma and association with disease risk and prognosis: a case-control study.
- Published in:
- Frontiers in Genetics, 2024, p. 1, doi. 10.3389/fgene.2024.1341822
- By:
- Publication type:
- Article
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD".
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2768, doi. 10.3390/cancers14112768
- By:
- Publication type:
- Article
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 12, p. 3355, doi. 10.3390/jcm11123355
- By:
- Publication type:
- Article
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
- Published in:
- Annals of Hematology, 2007, v. 86, n. 5, p. 369, doi. 10.1007/s00277-007-0258-x
- By:
- Publication type:
- Article